Hemophilia B Gene Therapy Shows Durable Response at 5 Years: 96% Reduction in Bleeds Maintained

How Long Does Hemophilia B Gene Therapy Last?

The central question for any gene therapy is durability — how long the therapeutic effect lasts. Long-term HOPE-B data has been encouraging. In the pivotal trial published in the New England Journal of Medicine, factor IX activity levels peaked at approximately 39% of normal in the months following treatment, then stabilized at a durable plateau. This pattern of early peak followed by stabilization is consistent with the AAV5 vector achieving stable episomal persistence in hepatocytes (liver cells).

The stability of expression after the initial plateau suggests that ongoing degradation is minimal. Researchers have noted that at observed rates of gradual decline, the majority of patients may maintain factor IX levels above 12% — the threshold for converting severe hemophilia to a mild phenotype — for many years. If levels eventually decline below therapeutic thresholds, re-treatment with alternative AAV serotype vectors is being explored as a potential future option, since anti-AAV5 antibodies from the initial treatment preclude re-dosing with the same vector.

What Are the Clinical Benefits After Long-Term Follow-Up?

The clinical impact of sustained factor IX expression has been transformative for treated patients. In the pivotal HOPE-B trial, the annualized bleeding rate (ABR) decreased from a baseline of approximately 4 events per year on prior prophylaxis to fewer than 1 event per year — a reduction of more than 90%. A substantial proportion of patients reported zero bleeding events during follow-up periods.

Freedom from regular factor IX prophylaxis has been maintained in the majority of treated patients. A small subset of patients whose factor IX levels settled near the lower end of the therapeutic range opted for additional low-dose prophylaxis coverage during high-risk activities. Patient-reported quality of life has shown sustained improvement, with patients reporting the ability to exercise, travel, and work without the planning burden of regular infusions for the first time in their lives.

Is Gene Therapy Safe Long-Term?

Long-term safety monitoring has been rigorous, including regular liver function tests, periodic liver imaging, and factor IX activity measurements. No new adverse events related to gene therapy have emerged during extended follow-up. The main safety event — ALT elevation in the first few months post-treatment — occurred in a subset of patients, was managed with short-course corticosteroids, and did not recur after resolution.

Concerns about AAV vector integration into the genome causing insertional mutagenesis or hepatocellular carcinoma have not materialized. Liver imaging has shown no nodular abnormalities, and integration site analysis indicates the vector predominantly exists as stable episomes (non-integrated DNA) rather than integrated into the host genome. Anti-AAV5 antibodies developed in all treated patients, which means re-dosing with the same AAV5 vector is not currently possible — though alternative serotype vectors (such as AAV8 and AAVrh10) are being explored as potential boosters.

What Does Hemgenix Cost and Is It Worth It?

Hemgenix carries a list price of $3.5 million for the single intravenous infusion — making it one of the most expensive drug treatments available. While this figure generates headline shock, it must be contextualized against the alternative: lifelong factor IX prophylaxis can cost several hundred thousand dollars per year for severe hemophilia B patients in the United States, with some estimates ranging from $500,000 to over $800,000 annually depending on the factor product used and dosing regimen.

At these prophylaxis costs, Hemgenix may become cost-saving compared to continued prophylaxis within several years if the treatment response remains durable. As long-term data continues to confirm sustained efficacy, the economic case strengthens. Many US insurers have begun covering Hemgenix, in some cases through outcomes-based contracts where payment is linked to maintained factor IX levels. The European Medicines Agency also approved etranacogene dezaparvovec. For patients, the non-financial value — freedom from frequent intravenous infusions, reduced bleeding anxiety, and improved quality of life — is substantial.